clinical trial · NCT06772870
A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
Friedreich AtaxiaDT-216P2Saline
brief summary
This purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of DT-216P2 administered either subcutaneously (SC) and intravenously (IV) in normal healthy participants. Approximately 36 participants will be enrolled into this study.
started
Feb 1, 2025
primary completion
Sep 1, 2025
completion
Dec 1, 2025
last updated
Feb 21, 2025
official title
A Phase 1, Double-Masked, Randomized, Placebo-Controlled, Single Ascending Dose Crossover Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Normal Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol